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Purpose
To investigate targeting of indoleamine 2.3 dioxygenase
(IDO) enzyme using a synthetic peptide vaccine admi-
nistered to patients with metastatic non small-cell lung
cancer (NSCLC).
Experimental design
In a clinical phase I study we treated 15 HLA-A2 positive
patients with stage III-IV NSCLC in disease stabilization
(SD) after standard chemotherapy. Patients were treated
with Imiquimod ointment and subcutaneous vaccinations
(100 µg IDO5 peptide, sequence ALLEIASCL, formulated
in 900 µL Montanide). Primary end point was toxicity.
Clinical benefit and immunity were assessed as secondary
endpoints.
Results
No severe toxicity was observed. One patient developed
a partial response (PR) after 1 year of vaccine treatment
while long-lasting disease stabilization (SD≥8.5 months)
was demonstrated in another 6 patients. The median
overall survival (OS) was 25.9 months. Patients demon-
strated significant improved OS (P=0.03) when com-
pared to the group of patients excluded due to HLA-A2
negativity. IDO specific CD8+ T cell immunity was
demonstrated by IFN-g Elispot and Tetramer staining.
FACS analyses demonstrated a significant reduction of
the Treg population (P=0.03) and a significant increase
in NK cell population (P=0.05) after the 6th vaccine
(2.5 months) compared to pre-treatment levels. Further-
more, expression of IDO was detected in 9/10 tumour
biopsies by immunohistochemistry. HPLC analyses of
Kynurenine/Tryptophan (Kyn/Trp) ratio in sera were
performed. In long term analyses of two clinical
responding patients the ratio of Kyn/Trp remained
stable.
Conclusion
The vaccine was well-tolerated with no severe toxicity
occurring. A median OS of 25.9 months was demon-
strated and long-lasting PR+SD were seen in 47% of the
patients.
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